ArticleCardiology research and practice2012
Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants.
Article in Cardiology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.Rheumatology (Oxford, England) · 2024Trial
- Injectable antifibrotic drug-loaded hydrogels reduce fibrosis and restore myogenesis by enhancing mitochondrial metabolism and cell mechanics in an in vitro coculture model.Materials today. Bio · 2026Article
- Impaired PIEZO1 function drives uterine hypercontractility in adenomyosis-associated dysmenorrhea.Human reproduction open · 2026Article
- Review
- The Preventive Role of Physical Activity in Systemic Sclerosis: A Cross-Sectional Study on the Correlation with Clinical Parameters and Disease Progression.International journal of environmental research and public health · 2022Article
- Single Donor Infusion of S-Nitroso-Human-Serum-Albumin Attenuates Cardiac Isograft Fibrosis and Preserves Myocardial Micro-RNA-126-3p in a Murine Heterotopic Heart Transplant Model.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- Red blood cells in type 1 diabetes and multiple sclerosis and technologies to measure their emerging roles.Journal of translational autoimmunity · 2022Review
- Peripheral Hybrid CBFrontiers in endocrinology · 2021Article
- Regulation of Extracellular Matrix Production in Activated Fibroblasts: Roles of Amino Acid Metabolism in Collagen Synthesis.Frontiers in oncology · 2021Review
- The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species.Antioxidants (Basel, Switzerland) · 2020Article
- State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders.Microvascular research · 2020Article
- Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis.Radiation research · 2019Article
- Interleukin-17: Friend or foe in organ fibrosis.Cytokine · 2019Review
- The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019Review
- Oxidative stress in the pathogenesis of systemic scleroderma: An overview.Journal of cellular and molecular medicine · 2018Review
- The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy.Frontiers in physiology · 2018Review
- Therapeutic potential of NADPH oxidase 1/4 inhibitors.British journal of pharmacology · 2017Review
- Role of redoximiRs in fibrogenesis.Redox biology · 2016Review
- A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face.BMJ case reports · 2016Article
- Cytokines in the immunopathology of systemic sclerosis.Seminars in immunopathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SYSTEMIC SCLEROSIS (SCLERODERMA: SSc) is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal organ failure, and death. One of the most important and early modulators of disease activity is thought to be oxidative stress. Evidence suggests that the free radical nitric oxide (NO), a key mediator of oxidative stress, can profoundly influence the early microvasculopathy, and possibly the ensuing fibrogenic response. Animal models and human studies have also identified dietary antioxidants, such as epigallocatechin-3-gallate (EGCG), to function as a protective system against oxidative stress and fibrosis. Hence, targeting EGCG may prove a possible candidate for therapeutic treatment aimed at reducing both oxidant stress and the fibrotic effects associated with SSc.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.